RCMI Coordinating Center (RCMI CC) Header Logo

Connection

Xue Zhu to Xenograft Model Antitumor Assays

Back to Details
This is a "connection" page, showing publications Xue Zhu has written about Xenograft Model Antitumor Assays.
Xue Zhu
Connection Strength
0.045
Xenograft Model Antitumor Assays
  1. Inkoom A, Ndemazie NB, Smith T, Frimpong E, Bulusu R, Poku R, Zhu X, Han B, Trevino J, Agyare E. Biological evaluation of novel gemcitabine analog in patient-derived xenograft models of pancreatic cancer. BMC Cancer. 2023 May 13; 23(1):435.
    View in: PubMed
    Score: 0.045
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.
RCMI CC is supported by the National Institute on Minority Health and Health Disparities, National Institutes of Health (NIH), through Grant Number U24MD015970. The contents of this site are solely the responsibility of the authors and do not necessarily represent the official views of the NIH

For technical support please contact support